Electroacupuncture Regulates Mitochondria-Endoplasmic Reticulum interactions via Fn1 in a Parkinson's Disease Model:...

Area of Science:

• Neuroscience
• Integrative Medicine
• Molecular Biology

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss and disrupted mitochondria-associated endoplasmic reticulum membranes (MAMs).
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a common neurotoxin used to induce Parkinson's disease models in research.
• Mitochondria-associated endoplasmic reticulum membranes (MAMs) play a critical role in cellular homeostasis and are implicated in neurodegenerative diseases.

Purpose of the Study:

• To investigate the efficacy of electroacupuncture (EA) in alleviating MPTP-induced Parkinson's disease symptoms.
• To elucidate the underlying molecular mechanisms of EA's neuroprotective effects using RNA sequencing (RNA-seq).
• To identify key genes and pathways involved in EA's therapeutic action on Parkinson's disease.

Main Methods:

• Established a Parkinson's disease mouse model using MPTP administration.
• Administered EA to specific acupoints (GV20 and GB34) and used sham EA as a control.
• Assessed neuroprotection via behavioral tests, immunohistochemistry, Western blotting, and MAM integrity analysis (electron microscopy, immunofluorescence).
• Utilized RNA-seq and protein-protein interaction (PPI) analysis to identify differentially expressed genes, with validation by qRT-PCR.

Main Results:

• EA treatment significantly improved motor performance and dopaminergic neuron markers (tyrosine hydroxylase) in MPTP-treated mice.
• EA enhanced the structural integrity of MAMs in dopaminergic neurons and reduced alpha-synuclein aggregation.
• RNA-seq identified 32 MAM-associated genes, highlighting fibronectin-1 (Fn1) as a key regulator upregulated by EA.
• Upregulation of Fn1 by EA suggests its role in stabilizing MAMs and conferring neuroprotection.

Conclusions:

• EA at GV20 and GB34 acupoints demonstrates therapeutic potential for Parkinson's disease.
• EA alleviates motor and neural impairments by modulating fibronectin-1 (Fn1) expression.
• The study suggests Fn1 and MAM-associated pathways are crucial targets for EA's neuroprotective effects in Parkinson's disease.